Sepracor Considers Partnering Late-stage Internal CNS Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Progress not “gated” by partnering, but cost/risk sharing means speedier development, CEO says.
You may also be interested in...
Japanese Dainippon Sumitomo Pharma To Acquire Sepracor For $2.6 Billion
The share price of Sepracor surged by over 25 percent to a high of $22.80 before trading was halted mid-day on Sept. 2, amid speculation of an imminent takeover by Japan's Dainippon Sumitomo Pharma
Sepracor Surges Amid Dainippon Takeover Talk
If the $2.7 billion deal materializes, Japanese pharma would gain sales force for lurasidone plus promising CNS candidates.
Sepracor Surges Amid Dainippon Takeover Talk
If the $2.7 billion deal materializes, Japanese pharma would gain sales force for lurasidone plus promising CNS candidates.